ReachMD CME

High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?


Listen Later

CME credits: 0.25
Valid until: 08-02-2023
Claim your CME credit at https://reachmd.com/programs/cme/high-risk-hfref-who-will-benefit-most-from-novel-therapies/13297/

Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.

...more
View all episodesView all episodes
Download on the App Store

ReachMD CMEBy ReachMD

  • 4.3
  • 4.3
  • 4.3
  • 4.3
  • 4.3

4.3

3 ratings